Majethia U - Search Results

Save citations to file

Email citations

Your saved search

Your RSS Feed

Page 1

Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea.

Tremblay G, Majethia U, Breeze JL, Kontoudis I, Park J. Tremblay G, et al. Among authors: majethia u. Clinicoecon Outcomes Res. 2016 Sep 19;8:485-493. doi: 10.2147/CEOR.S110553. eCollection 2016. Clinicoecon Outcomes Res. 2016. PMID: 27698565 Free PMC article.

Budget Impact and Incremental Survival Benefit of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Brazil.

Majethia U, Tremblay G, Borges L, Jones T, Forsythe A, Pomerantz D, Clark OA. Majethia U, et al. Value Health. 2014 Nov;17(7):A623. doi: 10.1016/j.jval.2014.08.2211. Epub 2014 Oct 26. Value Health. 2014. PMID: 27202196 Free article. No abstract available.

Economic Burden of Chemotherapy Related Toxicities in Third Line Metastatic Breast Cancer Patients.

Majethia U, Tremblay G, He YP, Faria C, Mccutcheon S, Kopenhafer L, Forsythe A. Majethia U, et al. Value Health. 2014 Nov;17(7):A628. doi: 10.1016/j.jval.2014.08.2242. Epub 2014 Oct 26. Value Health. 2014. PMID: 27202223 Free article. No abstract available.

Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Spain: Management in the Later Line of Therapy.

Tremblay G, Majethia U, Kontoudis I, De Rosendo J. Tremblay G, et al. Among authors: majethia u. J Health Econ Outcomes Res. 2015 Oct 21;3(2):180-193. doi: 10.36469/9834. eCollection 2016. J Health Econ Outcomes Res. 2015. PMID: 37663315 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4 results

Search Page

Filters